SCHEMBL3764174

SCHEMBL3764174

CCOc1ccc(Nc2nccc3[nH]nc(C)c23)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 6/20 0.46
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
SYK P43405 2/20 0.45
TTBK1 Q5TCY1 1/20 0.44
TTBK2 Q6IQ55 1/20 0.44
LRRK2 Q5S007 2/20 0.44
SHMT2 P34897 1/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TP53 P04637 1/20 0.42
NFKB1 P19838 1/20 0.41
RXFP1 Q9HBX9 2/20 0.41
PRNP P04156 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768520 0.85 PTK6 (0.51) CACNA2D1SYK
SCHEMBL3775329 0.84 LRRK2 (0.61) NPC1MAPTRAB9ALRRK2SMN1; SMN2
SCHEMBL3763899 0.81 GRM4 (0.51) NPC1MAPTRAB9ALRRK2
SCHEMBL3775370 0.81 LRRK2 (0.63) RAB9ALRRK2SMN1; SMN2
SCHEMBL3774794 0.81 GRM4 (0.50) MAPTLRRK2HPGD
SCHEMBL3777380 0.81 DHODH (0.52) MAPTSYKLRRK2
SCHEMBL3771247 0.79 LRRK2 (0.43) MAPTLRRK2
SCHEMBL3770143 0.78 DHODH (0.53) LRRK2
SCHEMBL3768966 0.78 LRRK2 (0.45) LRRK2
SCHEMBL3766326 0.78 HTT (0.49) ALDH1A1MAPTLRRK2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
EP-2408772-B1 COMPOUNDS MEDICAL RES COUNCIL TECHNOLOGY (GB) 2015-07-01 EP disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320870-A1 COMPOUNDS CBR3, CNR1, HCAR3 CACNA2D1 4351/4885ALDH1A1 2980/4885NPC1 230/4885
US-20100317646-A1 COMPOUNDS CBR3, CNR1, HCAR3 CACNA2D1 4355/4885ALDH1A1 2975/4885NPC1 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.